AGIOAGIOS PHARMACEUTICALS, INC.
Pharmaceutical Preparations
- Revenue
- $54M
- 48% YoY
- Operating margin
- -873.9%
- 25% YoY
- EBITDA
- −$467M
- 11% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired97% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $0 | $14M | $27M | $36M | $54M | 48% |
| Operating income | −$378M | −$389M | −$391M | −$426M | −$472M | 11% |
| Net income | $1.6B | −$232M | −$352M | $674M | −$413M | 161% |
| Operating cash flow | −$407M | −$309M | −$296M | −$390M | −$373M | 4.3% |
| Capex | $6M | $5M | $999K | $2M | $4M | 156% |
| Stock-based comp | $54M | $49M | $45M | $43M | $53M | 23% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $371K · 3
- Net
- −$371K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 63 | 120 |
| FY2024 | — | — | 76 | 91 |
| FY2023 | — | — | 51 | 92 |
| FY2022 | — | — | 65 | 89 |
| FY2021 | — | — | 76 | 99 |